Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 3 | 2 | 5 |
| 2014 | 1 | 7 | 8 |
| 2015 | 3 | 4 | 7 |
| 2016 | 3 | 9 | 12 |
| 2017 | 75 | 67 | 142 |
| 2018 | 75 | 69 | 144 |
| 2019 | 25 | 23 | 48 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
The Mechanisms of the Growth Inhibitory Effects of Paclitaxel on Gefitinib-resistant Non-small Cell Lung Cancer Cells. Cancer Genomics Proteomics. 2021 Sep-Oct; 18(5):661-673.
-
Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021 08 01; 96(8):934-944.
-
Downregulation of ACE2 expression by SARS-CoV-2 worsens the prognosis of KIRC and KIRP patients via metabolism and immunoregulation. Int J Biol Sci. 2021; 17(8):1925-1939.
-
COVID-19 infection can cause chemotherapy resistance development in patients with breast cancer and tamoxifen may cause susceptibility to COVID-19 infection. Med Hypotheses. 2020 Oct; 143:110091.
-
Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report. Anticancer Drugs. 2019 11; 30(10):1052-1054.
-
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer. 2019 11; 121:144-153.
-
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med. 2019 08 22; 381(8):727-738.
-
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. Clin Cancer Res. 2019 12 15; 25(24):7312-7319.
-
Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells. Cancer Sci. 2019 Oct; 110(10):3275-3287.
-
TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1. Clin Cancer Res. 2019 11 15; 25(22):6827-6838.